| Trial ID # | NCT03558139 |
| Phase | Ib |
| Drug Class | Immunotherapy: Checkpoint Inhibitors/PD-L1 |
| Drug Name | Avelumab |
| Alternate Drug Names | Anti programmed death ligand 1 monoclonal antibody, Anti-PD-L1, MSB0010718C, Bavencio |
| Drugs in Trial | Avelumab, Magrolimab |
| Eligible Participant | Platinum resistant or refractory ovarian cancer |
| Patients Enrolled | 18 |
| Therapy Setting | Recurrence |
| Study Design | Open-Label, Non-randomized |
| Endpoints | DCR, evaluated per RECIST |
| Efficacy | DCR: 56% (10SD, n=18) |
| Clinically Significant Adverse Events | Serious AE: |
| Conclusion | Avelumab+magrolimab is a novel, well-tolerated combination with a 56% stable disease rate in ovarian cancer patients |
| Reference | Lakhani NJ et al. A phase Ib study of the anti-CD47 antibody magrolimab with the PD-L1 inhibitor avelumab (A) in solid tumor (ST) and ovarian cancer (OC) patients. J Clin Oncol (2020) 38 (suppl 5; abstr 18) |